Loss of MED12 promotes the transition of a mesenchymal phenotype, which is accompanied by chemotherapy resistance in colon cancer patients and resistance to the tyrosinase inhibitor gefitinib in lung cancer. This evidence concerns the gene TYR and lung cancer.